MedDataX Logo

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT04490031 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2020-07-28

No results posted yet for this study

Summary

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

Conditions

  • Ketamine Adverse Reaction

Interventions

DRUG

Ketamine Hydrochloride

patient in Ketamine group will be given Ketamine as sedative agent

Sponsors & Collaborators

  • Universiti Kebangsaan Malaysia Medical Centre

    lead OTHER

Principal Investigators

  • Ian Chik, MD · Universiti Kebangsaan Malaysia Medical Centre

  • Norma mohamad, MD · Universiti Kebangsaan Malaysia Medical Centre

  • Zamri Zuhdi, MD · Universiti Kebangsaan Malaysia Medical Centre

  • Azlanudin Azman, MD · Universiti Kebangsaan Malaysia Medical Centre

  • Muhammad Hafiz Ismail, MD · Universiti Kebangsaan Malaysia Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-12-31
Completion
2021-04-30
FDA Drug
Yes

Countries

  • Malaysia

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490031 on ClinicalTrials.gov